These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26516102)

  • 1. Adverse events and treatment failure leading to discontinuation of recently approved antipsychotic drugs in schizophrenia: A network meta-analysis.
    Tonin FS; Piazza T; Wiens A; Fernandez-Llimos F; Pontarolo R
    Schizophr Res; 2015 Dec; 169(1-3):483-485. PubMed ID: 26516102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.
    Kishi T; Ikuta T; Sakuma K; Okuya M; Iwata N
    J Psychiatr Res; 2021 Jun; 138():444-452. PubMed ID: 33964682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
    Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
    J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
    Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM
    Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis.
    Brandt L; Schneider-Thoma J; Siafis S; Efthimiou O; Bermpohl F; Loncar L; Neumann K; Hasan A; Heinz A; Leucht S; Gutwinski S
    Lancet Psychiatry; 2022 Mar; 9(3):232-242. PubMed ID: 35183280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
    Lao KS; He Y; Wong IC; Besag FM; Chan EW
    CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.
    Leucht S; Barnes TR; Kissling W; Engel RR; Correll C; Kane JM
    Am J Psychiatry; 2003 Jul; 160(7):1209-22. PubMed ID: 12832232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Oya K; Kishi T; Iwata N
    Hum Psychopharmacol; 2014 Sep; 29(5):483-91. PubMed ID: 25087702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis.
    Feber L; Peter N; Schneider-Thoma J; Siafis S; Bighelli I; Hansen WP; Prates Baldez D; Salanti G; Keefe RSE; Engel RR; Leucht S
    Syst Rev; 2023 Mar; 12(1):54. PubMed ID: 36959619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials.
    Kishi T; Matsuda Y; Nakamura H; Iwata N
    J Psychiatr Res; 2013 Feb; 47(2):149-54. PubMed ID: 23131856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.
    Citrome L
    CNS Drugs; 2013 Nov; 27(11):879-911. PubMed ID: 24062193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials.
    Zheng W; Wang S; Ungvari GS; Ng CH; Yang XH; Gu YH; Li M; Xiang YQ; Xiang YT
    J Clin Psychopharmacol; 2017 Jun; 37(3):341-346. PubMed ID: 28383359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.